89bio
San Francisco, California, United States · Biopharma, Biotechnology, Health Care
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertrigl
Key facts
- Headquarters
- San Francisco, California, United States
- Employees
- 112
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- 89bio.com
- Company page
Recent activity at 89bio
Leadership
- Francis Sarena, Chief Operating Officer
- Paul Shin, Chief Executive Officer
- Bethany Evans, Human Resources Specialist
- Merav Barki, Sr. Director Global Finance
- Joanna Montgomery
- Brendan O'Connell, Finance and Accounting Senior Executive
- Chen Almog, Accounts Payable Manager
- Leslie Fok, Strategic Commercial Leader
- Rohan Palekar, Chief Executive Officer
- Teresa Perney, Chief Regulatory and Quality Officer
- Francis Sarena, Chief Operating Officer
- Merav Barki, Sr. Director Global Finance
Verified email and direct lines for 89bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
89bio in the news
- Brugnoli develops fabric with 89% bio-based content - World Bio Market Insights (Mar 20, 2026)
- Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters (Sep 18, 2025)
- Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug - Fierce Biotech (Sep 18, 2025)
- Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug - STAT (Sep 18, 2025)
- How a small Bay Area drug company landed a potential $3.5 billion acquisition despite pharma funding drought - The Business Journals (Oct 01, 2025)
- After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks - Fierce Biotech (Oct 02, 2025)
- Pegozafermin Enters Phase 3 Clinical Trial Program for MASH, Fibrosis - HCPLive (Mar 12, 2024)
- Pegazofermin Enters Phase 3 ENLIGHTEN Clinical Trial Program for MASH - Patient Care Online (Mar 13, 2024)
Companies similar to 89bio
- Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Journey Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Aurinia Pharma · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Redx · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Timberlyne Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About 89bio: questions and answers
What does 89bio do?
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertrigl
Where is 89bio headquartered?
89bio is headquartered in San Francisco, California, United States.
How many employees does 89bio have?
89bio has about 112 employees.
Who leads 89bio?
Paul Shin is a Chief Executive Officer at 89bio.
What is the latest news on 89bio?
On Jan 29, 2025, 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy